{"entity":{"id":"nct05263583","kind":"trial","name":"Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma","aka":[],"tldr":"A phase 2 trial of Sepantronium Bromide in non-Hodgkin lymphoma, burkitt lymphoma and diffuse large B-cell lymphoma, run by Cothera Bioscience, Inc, active and no longer recruiting.","summary":"Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma is a phase 2 interventional study registered as NCT05263583 by Cothera Bioscience, Inc, with 14 participants enrolled, started 2022-12-09 and due to reach its primary completion in 2025-03-01. Interventions recorded: Sepantronium Bromide.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05263583","url":"https://clinicaltrials.gov/study/NCT05263583"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","burkitt-lymphoma","dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05263583","phase":"2","setting":"A Phase 2, Multicenter, Open Label Dose-ranging Study of Sepantronium Bromide in Patients With Relapsed/Refractory c-Myc Rearranged High-grade B-cell Lymphoma (HGBCL)","sponsor":"Cothera Bioscience, Inc","enrolled":14,"outcomes":[]},"route":"/trials/nct05263583/","neighbours":{"cancer":[{"id":"burkitt-lymphoma","kind":"cancer","name":"Burkitt lymphoma","route":"/cancers/burkitt-lymphoma/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}